CPC C12N 5/0636 (2013.01) [A61K 35/17 (2013.01); A61K 39/0011 (2013.01); A61K 2035/124 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/585 (2013.01); C12N 2501/515 (2013.01); C12N 2510/02 (2013.01); C12N 2511/00 (2013.01)] | 5 Claims |
1. A method of treating cancer in a human subject in need thereof, optionally a histoincompatible human recipient, which comprises administering a composition comprising a recombinant primary human T cell or progeny thereof, which primary human T cell or progeny thereof:
(i) has been modified to functionally impair and/or to reduce expression of the endogenous T cell receptor (TCR), and
(ii) has been further modified to express at least one functional exogenous non-TCR chimeric receptor comprising:
(1) at least one ligand binding domain which binds to a ligand expressed by human cancer cells of the treated subject and
(2) at least one signaling domain.
|